Clinical trialNCT03615924TerminatedPhase 3Interventional

Effect of Ticagrelor vs. Placebo in the Reduction of Vaso-occlusive Crises in Pediatric Patients With Sickle Cell Disease

SponsorAstraZenecaEnrollment193Sickle Cell Disease

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The purpose of the study is to Evaluate the Effect of Ticagrelor versus Placebo in Reducing the Rate of Vaso-Occlusive Crises in Paediatric Patients with Sickle Cell Disease

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Anders Berggren, MD, PhD
AstraZeneca
Study Director
clinicaltrials.gov ↗
Matthew Heeney, MD
Harvard Medical School (HMS and HSDM)
Principal Investigator
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

55 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Belgium

Research Site
Brussels, Belgium
Research Site
Edegem, Belgium

Brazil

Research Site
Porto Alegre, Brazil
Research Site
Rio de Janeiro, Brazil
Research Site
Salvador, Brazil
Research Site
São Paulo, Brazil
Research Site
São Paulo, Brazil

Egypt

Research Site
Al Sharkeya, Egypt
Research Site
Alexandria, Egypt
Research Site
Cairo, Egypt
Research Site
Cairo, Egypt
Research Site
Cairo, Egypt
Research Site
Dakahlia, Egypt

Ghana

Research Site
Accra, Ghana
Research Site
Ho, Ghana
Research Site
Kumasi, Ghana

Greece

Research Site
Athens, Greece

India

Research Site
Mumbai, India
Research Site
Nagpur, India
Research Site
Nagpur, India
Research Site
Pune, India
Research Site
Pune, India
Research Site
Wardha, India

Italy

Research Site
Catania, Italy
Research Site
Naples, Italy
Research Site
Padova, Italy
Research Site
Verona, Italy

Kenya

Research Site
Kisumu, Kenya
Research Site
Nairobi, Kenya
Research Site
Siaya, Kenya

Lebanon

Research Site
Beirut, Lebanon
Research Site
Tripoli, Lebanon

South Africa

Research Site
Cape Town, South Africa
Research Site
Soweto, South Africa

Spain

Research Site
Barakaldo, Spain
Research Site
Barcelona, Spain
Research Site
Madrid, Spain
Research Site
Madrid, Spain

Tanzania

Research Site
Mbeya, Tanzania

Turkey (Türkiye)

Research Site
Antalya, Turkey (Türkiye)

15 more sites on the registry record.ClinicalTrials.gov ↗

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

PlaceboTicagrelor →

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 26 Sept 2018
Primary completion: 13 Aug 2020
Completion: 13 Aug 2020
Last update posted: 9 Apr 2021
Registered enrollment: 193
Registry id: NCT03615924

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.